Summary

  • Cardlytics sold the Bridg platform in March 2026, yet a director-indemnification obligation inherited with its 2021 acquisition remained with Cardlytics and required a $6,441,649.40 September payment.
  • The June accounts carried a rounded $6.5 million accrual and said $4.0 million was expected from D&O insurance, but no recovery asset would be recognised until a final amount was agreed with the insurer.
  • The settlement gives Cardlytics control of most related insurance claims and proceeds. That improves its ability to pursue reimbursement; it does not establish coverage, timing or cash collection.

The platform left before the promise did

There are two Bridg exits in Cardlytics’s 2026 record. Only one removed an operating platform.

On 24 March, Cardlytics completed the sale of the assets, properties and rights primarily related to Bridg. PAR Technology delivered 1,810,222 PAR shares as consideration. Cardlytics’s June 10-Q says it then sold those shares for $23.0 million net of fees, recorded a $13.9 million divestiture gain and $2.0 million of divestiture costs, and classified Bridg as discontinued operations.

On 4 September, Cardlytics entered another agreement bearing the Bridg name. This one did not transfer software, customers or platform rights. It resolved a claim by Amit Jain, Bridg’s founder and former chief executive, for advancement and indemnification of costs connected with litigation.

The link goes back to the acquisition. Cardlytics agreed in April 2021 to acquire Bridg for an initial $350 million in cash, subject to adjustments, plus anniversary payments tied to revenue formulae. The 2026 settlement recitals add the fact that matters here: Bridg had signed a director-indemnification agreement with Jain in 2014, and Cardlytics assumed those obligations through the merger.

An asset sale does not automatically answer what happened to every contract inherited in the purchase. The public filings do not suggest that Jain’s rights moved to PAR. Instead, Cardlytics continued to negotiate the obligation and accounted for it within discontinued operations because it was directly attributable to the Bridg acquisition. “Discontinued” described the presentation of the former business, not the disappearance of every cash claim attached to its history.

The June accounts kept the liability gross

The June filing provides the cleanest bridge from uncertainty to the later payment. Cardlytics said Jain’s allocated portion of the DailyGobble settlement was $5.3 million and that he had claimed another $1.8 million of attorney fees. After further negotiations, the company increased its accrual by $5.2 million. At quarter-end it carried $5.3 million for the settlement and $1.2 million for attorney fees: $6.5 million in total.

The filing also said Cardlytics expected $4.0 million to be covered by the applicable directors’ and officers’ insurance policy. It did not net that expectation against the obligation. It said a corresponding insurance recovery asset would be recognised only once Cardlytics had agreed a final settlement amount with the insurance provider.

That sequence blocks a tempting shortcut. Subtracting $4.0 million from a rounded $6.4 million produces $2.4 million, but $2.4 million was not the disclosed net cost. One side of that subtraction became an exact payment obligation; the other remained management’s expectation about disputed coverage. Different recognition conditions, control parties and cash dates prevent the two numbers from being treated as one settled ledger.

The distinction is not cosmetic. A booked liability can reduce earnings before it consumes cash. An insurance recovery can be delayed, disputed, reduced by limits or exclusions, or settled on terms that do not match the underlying payment. Investors need the gross outflow, any recognised recovery asset and actual insurance proceeds reported separately before they can reconstruct the economic burden.

The settlement fixed a number more precise than the headline

The settlement agreement required Cardlytics to initiate a wire of exactly $6,441,649.40 on or before 4 September. Its components were $5,250,000 for Jain’s portion of the DailyGobble settlement, $51,663.60 of associated borrowing costs and $1,139,985.80 for specified legal fees.

Cardlytics’s 11 September 8-K rounds that aggregate to $6.4 million and says it is consistent with the June accrual of $6.5 million, which comprised $5.3 million for settlement and $1.2 million for attorney fees. The exact payment is $58,350.60 below the rounded accrual. That is not enough information to claim a precise accrual release: both June components were reported in tenths of a million, and the agreement includes borrowing costs that the quarterly description did not itemise.

The contract also describes a sequence, not a single clean severance. Jain was to dismiss his Delaware action with prejudice within two business days after receiving the payment. Mutual releases attached to specified payment and dismissal conditions. Yet Cardlytics also agreed to advance reasonable accrued and future fees for the Scottsdale insurance actions and related matters under the indemnification agreement. Jain retained specified rights for future proceedings that did not yet exist.

The $6.44 million wire therefore settled the defined current claim between Cardlytics and Jain. It did not prove that all future legal spending connected with the matter had ended.

Cardlytics bought control of the insurance fight, not the outcome

The most economically important non-cash term is the assignment. Jain transferred to Cardlytics most of his rights in two Scottsdale Insurance actions: the claims and defences, the ability to prosecute or settle them, and the rights to judgments, awards, recoveries or settlement proceeds. Cardlytics obtained sole authority to direct those actions, subject to the agreement’s cooperation and expense terms.

Jain did not transfer everything. He retained claims for breach of the implied covenant of good faith and fair dealing and agreed to dismiss them after the broader assignment became effective. That carve-out matters because “Cardlytics controls the insurance litigation” would otherwise be too broad. It controls the assigned coverage dispute; it does not own every theory Jain had asserted.

Control has real value. Cardlytics no longer has to fund the underlying settlement while depending entirely on another party’s litigation choices to pursue the coverage it expects. It can select strategy, assess a settlement offer and direct the claims whose proceeds would reimburse it. But this is procedural authority over a disputed asset. It is not authority over Scottsdale, and it cannot compel the carrier or a court to produce $4.0 million.

The issuer’s wording remains appropriately conditional. Cardlytics says it is seeking reimbursement that it believes should apply. The frozen record does not say the insurer admitted coverage, accepted the $4.0 million figure, agreed a payment date or transferred cash. Until one of those events appears, the assignment belongs in the control column, not the collection column.

A sale perimeter and an obligation perimeter need separate ledgers

The Bridg sequence is useful beyond its size. Software acquisitions contain operating assets, employee arrangements, customer contracts, earnouts, indemnities, insurance rights, litigation and retained liabilities. A later asset sale can transfer some of those components without recreating the original merger in reverse.

Cardlytics’s disclosures show three different boundaries. The March transaction moved the platform assets. The September settlement fixed the current amount owed to Jain and narrowed the direct dispute. The assignment moved control of most insurance claims to the party required to fund the settlement. None of those steps alone establishes the final insurance economics.

That is why the correct market question is not whether Cardlytics “got rid of Bridg”. It is which Bridg-related assets, obligations and recovery rights left, remained or changed hands on each date. The platform sale closed. The inherited promise survived it. The current claim became an exact payment obligation. The recovery remained contested.

Primary evidence: Cardlytics’s 2021 acquisition filing, March 2026 sale filing, June 2026 Form 10-Q, September Form 8-K and the settlement agreement.